Category Lobbying

Antimicrobial Resistance Needs New R&D Models, NGOs Say

A group of non-governmental organisations organised a side event to the World Health Assembly to discuss the growing issue of antimicrobial resistance, the way to incentivise research and development for new antibiotics, and the imperative of affordability and accessibility of new products. The speakers mentioned alternative models, such as delinking the cost of research from the price of the medicines, underlined the high prices of vaccines, and the importance of systems of infection prevention and control.

Coordinated Global Solution Needed To Ensure Universal Vaccine Supply, Speakers Say

Shortages of vaccines are a worldwide problem with tremendous impact on health, affecting countries of all income groups and regions, speakers said at a recent industry event. Different possible solutions for shortages of vaccines were suggested during the panel discussion.

Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says

The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus.

IFPMA Priorities At WHA: Election, Antibiotics, Cancer, Pandemics

The new head of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has hit the ground running in Geneva, and is weighing in on a variety of policy issues, this week providing a list of priorities for the research-based pharma industry at the upcoming annual World Health Assembly.

MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals

The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines.

The True Believer: An Interview With New IFPMA Director General Thomas Cueni

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has long been at the centre of global public health policy in Geneva, representing industry from around the world. Now at a critical moment of change in the policymaking machinery, a new leader, Thomas Cueni of Switzerland, has taken over. Intellectual Property Watch recently sat down with him to discuss his views and vision going forward, and discovered his intellectual pragmatism and diverse experience which promise to open an ambitious new era for the association and global health policy.